-

Electromed, Inc. to Join Russell 2000® and Russell 3000® Indexes

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025.

"We are pleased that Electromed is joining these important market indices, which serve as leading benchmarks for institutional investors and as the basis for numerous index-linked financial products,” said Jim Cunniff, Electromed’s President and Chief Executive Officer. "This is an important milestone in Electromed’s growth, and a testament to the significant progress Electromed has made in enhancing shareholder value over the past year."

The broad-market Russell 3000 Index includes the largest 3,000 U.S. public companies by market capitalization. The Russell 2000 Index is a subset of the broader Russell 3000 Index limited to small-cap companies. Both are widely used by investment managers and institutional investors as the basis for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell US Indexes. Russell US Indexes are part of FTSE Russell’s suite of index offerings.

For more information on the Russell 2000® and Russell 3000® Indexes and the Russell indexes reconstitution, visit the "Russell Reconstitution" section on the FTSE Russell website.

About Electromed, Inc.

Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.

Contacts

Brad Nagel, Chief Financial Officer
(952) 758-9299
investorrelations@electromed.com

Mike Cavanaugh, Investor Relations
ICR Healthcare
(617) 877-9641
mike.cavanaugh@icrhealthcare.com

Electromed, Inc.

NYSEAM:ELMD

Release Versions

Contacts

Brad Nagel, Chief Financial Officer
(952) 758-9299
investorrelations@electromed.com

Mike Cavanaugh, Investor Relations
ICR Healthcare
(617) 877-9641
mike.cavanaugh@icrhealthcare.com

More News From Electromed, Inc.

Electromed, Inc. Announces Fiscal 2025 Third Quarter Results

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. Announces Fiscal 2025 Third Quarter Results...

Electromed, Inc. Schedules its Third Quarter Fiscal 2025 Financial Results Conference Call for May 13, 2025 at 5:00 p.m. ET

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2025 third quarter ended March 31, 2025, on May 13, 2025 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call...

Electromed, Inc. Announces Share Repurchase Authorization

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that on March 6, 2025, its board of directors authorized the repurchase of up to $5.0 million of Electromed common stock. The timing and amount of share repurchases pursuant to the authorization, if any, will be determined by management based on market conditions and other considerations. Repurchases may be made from time to time on the...
Back to Newsroom